Centre Launches Serum Institute’s Pneumococcal Vaccine Pneumosil
Centre Launches Serum Institute’s Pneumococcal Vaccine Pneumosil: Union Health Minister Harsh Vardhan launched the country's first pneumococcal conjugate vaccine 'Pneumosil' developed by Serum Institute of India in collaboration with partners like the Bill and Melinda Gates Foundation.
On the occasion, Vardhan remarked that the vaccines are used in 170 countries and every third child in the world is immunised with the manufacturer's shots, the health ministry said in a statement. The minister further said that SIIPL developed and got license of the first indigenous Pneumococcal Conjugate Vaccine (PCV) from the government during COVID-19 pandemic lockdown, in line with Prime Minister Narendra Modi's vision of Atmanirbhar Bharat', it said. Serum Institute's first indigenous Pneumococcal Conjugate Vaccine will be available in the market under the brand name 'Pneumosil' at an affordable price in single dose (vial and pre-filled syringe) and multidose (vial) presentations.
"Pneumosil has been extensively evaluated in five randomised and controlled clinical trials, and has demonstrated comparable safety and immunogenicity against licensed pneumococcal vaccines across diverse populations of India and Africa, where Pneumosil was administered to adults, toddlers and infants using different vaccination schedules," Vardhan was quoted as saying in the statement. During clinical trials, Pneumosil was found to be safe and effective in the prevention of pneumonia and based on which Pneumosil has been licensed by the Drugs Controller General of India in July 2020 after approval from subject expert committee (SEC), he said.
Comments
Post a Comment